News | Oncology Diagnostics | August 24, 2018

European team develops magnetoferritin compound to improve the quality of MRI imaging for oncology diagnostics

Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.


August 24, 2018 — A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing malignant cells and to provide additional opportunities for cancer treatment. The magnetoferritin compound is the main element of the new system. The research article has been published in Advanced Functional Materials.

The research team consists of scientists from the National University of Science and Technology (NUST) MISIS (Moscow), the Technical University of Munich, Helmholtz Zentrum München, the University of Duisburg-Essen, and the University of Oldenburg.

The lack of accuracy (contrast) in imaging is a common problem of non-invasive diagnosis. Contrast agents, compounds that are introduced into the body before a diagnostic procedure to enhance the response and make affected cells more visible on a tomograph, can be used to solve this problem in magnetic resonance imaging (MRI). Paramagnetic gadolinium particles and superparamagnetic iron particles are among these agents. However, even in small quantities, these substances — alien to the human body — can potentially be dangerous.

"The international research team, including Dr. Ulf Wiedwald, a visiting professor at the NUST MISIS Biomedical Nanomaterials Laboratory, has developed a unique injection diagnosis system based on magnetoferritin. The developed system will significantly improve the quality of MRIs and optical diagnosis," said Alevtina Chernikova, rector of NUST MISIS.

Magnetoferritin is a compound consisting of endogenous human protein (ferritin) and a magnetic nucleus. The development and testing of the compound was conducted following the existing protocol for the synthesis of magnetoferritin, but was improved for the effective capture of tumor cells. The high concentration of magnetoferritin in tumor tissue made it possible to obtain a hypoallergenic contrast agent that is perfectly compatible with the human body.

"An intravenous injection of magnetoferritin has been proposed. Then, spreading with the blood flow, [the magnetoferritin] will be captured by the targeted tumor cells. As has been shown in a large number of studies, these cells actively capture transferrin - the protein responsible for the transport of iron in the blood. The same receptors are capable of capturing the magnetoferritin as well. Once they get into the lysosomes of targeted cells, the magnetoferritin will further enhance the contrast signal," commented Wiedwald.

The system will also allow doctors to conduct therapy on tumor formations. If an MRI shows cancerous cells, they can be targeted by an electromagnetic field or light, which will lead to their heating and subsequent death.

For more information: www.onlinelibrary.wiley.com

Reference

Massner C., Sigmund F., Pettinger S., et al. Genetically Controlled Lysosomal Entrapment of Superparamagnetic Ferritin for Multimodal and Multiscale Imaging and Actuation with Low Tissue Attenuation. Advanced Functional Materials, March 13, 2018. https://doi.org/10.1002/adfm.201706793

Related Content

News | Magnetic Resonance Imaging (MRI)

November 24, 2021 — Royal Philips announced new AI-enabled innovations in MR imaging launching at the Radiological ...

Time November 24, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 22, 2021 — Adolescents and young adults with post-concussive symptoms who suffered three to five concussions ...

Time November 22, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 17, 2021 — The University of Michigan Health System recently became the first U.S. healthcare institution to ...

Time November 17, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
Videos | Radiation Therapy

Siemens and Philips demonstrated examples of new imaging software to convert MRI datasets into synthetic computed ...

Time November 15, 2021
arrow
News | Radiology Imaging

Noveember 11, 2021 — Siemens Healthineers and UC San Francisco have formed a research and innovation-driven ...

Time November 11, 2021
arrow
News | Computed Tomography (CT)

November 11, 2021 — Transcranial focused ultrasound can be used to treat degenerative movement disorders, intractable ...

Time November 11, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 11, 2021 — A multidisciplinary team of scientists based at the Universidad de Valladolid and the Centro ...

Time November 11, 2021
arrow
Feature | Artificial Intelligence | By Simon Rost

Confidence is like the autopilot on an airplane. It provides assurance and support that we are going in the right ...

Time November 08, 2021
arrow
Subscribe Now